Harri Järveläinen 🇫🇮🇺🇸🇨🇳🇦🇺 (@hulivili) 's Twitter Profile
Harri Järveläinen 🇫🇮🇺🇸🇨🇳🇦🇺

@hulivili

Biotech entrepreneur. Toxicologist. Economist. Plus a veterinarian! Obsessed with taking the coolest science into clinical PoC.

ID: 23552729

linkhttp://www.biotechgo.com calendar_today10-03-2009 03:46:06

557 Tweet

364 Followers

564 Following

Dennis Gong (@gongdennis) 's Twitter Profile Photo

Chinese biotech in 2025 🇨🇳. Lots of chatter, but still without a thorough look at what kinds of drugs China is actively developing. To address this, I reviewed 54 Chinese biopharma pipelines, highlighting notable deals, assets, and trends

Chinese biotech in 2025 🇨🇳. Lots of chatter, but still without a thorough look at what kinds of drugs China is actively developing.

To address this, I reviewed 54 Chinese biopharma pipelines, highlighting notable deals, assets, and trends
Harri Järveläinen 🇫🇮🇺🇸🇨🇳🇦🇺 (@hulivili) 's Twitter Profile Photo

Proud to have been part of this journey, especially as it is from my dear Home Country 🇫🇮! Continuing the progress in the clinic with €19M in funding. #valotx globenewswire.com/news-release/2…

Harri Järveläinen 🇫🇮🇺🇸🇨🇳🇦🇺 (@hulivili) 's Twitter Profile Photo

The good news: The FDA is confirming that max 3-month tox is needed for mAbs. Otherwise I don't see much change to regular animal testing requirements. The alternative methods encouraged sound exploratory / mechanistic. Unless there are any 'pilot case' volunteers out there?

Harri Järveläinen 🇫🇮🇺🇸🇨🇳🇦🇺 (@hulivili) 's Twitter Profile Photo

Driving different EVs in China is a blast. This one didn’t even have an English name, but it was awesome! Have to say most feel way nicer than a Tesla…

Harri Järveläinen 🇫🇮🇺🇸🇨🇳🇦🇺 (@hulivili) 's Twitter Profile Photo

New #pancreaticcancer data at #ESMOGI: Oral presentation of AGITG ASCEND Phase 2 trial (Abstract 260MO); Certepetide + gem/nab-P vs. gem/nab-P in 1L mPDAC. Looking forward to seeing how the double-dose certepetide is performing! $LSTA

New #pancreaticcancer data at #ESMOGI: Oral presentation of AGITG ASCEND Phase 2 trial (Abstract 260MO); Certepetide + gem/nab-P vs. gem/nab-P in 1L mPDAC. Looking forward to seeing how the double-dose certepetide is performing! $LSTA
Harri Järveläinen 🇫🇮🇺🇸🇨🇳🇦🇺 (@hulivili) 's Twitter Profile Photo

Remember to pay those patent fees in time! (I always find it nerve-racking that filings, as well as payments, are often done on the last day) science.org/content/blog-p…

Harri Järveläinen 🇫🇮🇺🇸🇨🇳🇦🇺 (@hulivili) 's Twitter Profile Photo

En route BOS-SAN - look at the marvelousness up in the air! Why does everyone (else) keep their window shades closed? This is a very American phenomenon…why?

Harri Järveläinen 🇫🇮🇺🇸🇨🇳🇦🇺 (@hulivili) 's Twitter Profile Photo

'Frontiers in Neuroscience: Emerging Biology and Therapeutics', July 21-22. For anyone working in neuroscience, this free 2-day virtual event from PBSS is a great opportunity: pbss.org/eventDetails/9… pbss.org/eventDetails/9…

Harri Järveläinen 🇫🇮🇺🇸🇨🇳🇦🇺 (@hulivili) 's Twitter Profile Photo

One of the companies I work with is stuck: US/EU CDMO release testing failing ONLY at their lab, batch can’t be released, trial on hold >2 mo. Not available for troubleshooting until Aug. Plus they want £200/hr for extra work (e.g. sharing raw data). Back to Asia next time!